Adial Pharma-Backed Purnovate Selects PNV-5030 As Pain Management Candidate

  • Adial Pharmaceuticals Inc ADIL has announced data in a preclinical model of pain reduction. Based on the data, Adial's subsidiary Purnovate Inc selected PNV-5030 as the lead compound for its program to develop pain management drugs.
  • PNV-5030 has been tested to be more than 1000-fold selective over the adenosine A1 receptor, which is known to have cardiovascular and central nervous system effects across several therapeutic indications. 
  • PNV-5030 has demonstrated more than 50 times greater solubility than other known selective adenosine compounds of the same class. 
  • In the most recent study, PNV-5030 was tested in a mouse model of somatic nociceptive pain. 
  • PNV-5030 alone exhibited a significant pain reduction compared to the control group and a similar effect to 1mg/kg morphine. 
  • PNV-5030 demonstrated a significant effect when administered with 1 mg/kg morphine compared to 1 mg/kg morphine alone. 
  • Combined with 1 mg/kg morphine, PNV-5030 achieved a similar level of pain reduction to the reduction obtained with 2mg/kg morphine. 
  • The results indicate the possibility of lowering the opioid dose to achieve a similar pain reduction.
  • The Company expects to advance PNV-5030 into clinical trials in 2022.
  • Price Action: ADIL shares are down 7.18% at $3.88 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefspain managementPain MedicationPreclinical Phase
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!